U.S. Markets open in 4 hrs 11 mins

CytRx Corporation (CYTR)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.61+0.10 (+20.72%)
At close: 4:00PM EDT
People also watch
Interactive chart
Previous Close0.50
Bid0.00 x
Ask0.78 x 11300
Day's Range0.50 - 0.65
52 Week Range0.36 - 3.28
Avg. Volume4,840,679
Market Cap92.57M
PE Ratio (TTM)-1.15
EPS (TTM)-0.53
Earnings DateJul 27, 2017 - Jul 31, 2017
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.00
Trade prices are not sourced from all markets
  • Benzinga7 days ago

    The Most Notable Abstracts Released Ahead Of ASCO 2017

    The American Society of Clinical Oncology, or ASCO, has scheduled its annual meeting on June 2–6, 2017, at McCormick Place, Chicago. The five-day event has Conquer Cancer Foundation as its lead sponsor. ...

  • Accesswire7 days ago

    Today's Research Reports on Biotech Stocks to Watch: Achillion Pharmaceuticals and CytRx

    NEW YORK, NY / ACCESSWIRE / May 19, 2017 / Despite the recent sell-off triggered by the recent health-care bill that is meant to take the place of the Affordable Care Act, the Biotech Industry has continued ...

  • PR Newswire8 days ago

    CytRx to Present Global Phase 3 Aldoxorubicin Clinical Data in Patients with Soft Tissue Sarcomas at the 2017 American Society of Clinical Oncology Annual Meeting

    LOS ANGELES, May 17, 2017 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the presentation of two abstracts at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6, 2017 in Chicago.  The first is an oral presentation featuring updated and more detailed results from the Company's global Phase 3 clinical trial evaluating aldoxorubicin versus investigator's choice in patients with relapsed and refractory soft tissue sarcomas (STS).  The other is a poster presentation describing updated data from an ongoing Phase 1/2 clinical trial combining aldoxorubicin with ifosfamide/mesna (I-M) in first- and second-line STS.